Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Imfinzi fails to meet main goals in head and neck cancer study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 02:55am EDT
A sign is seen at an AstraZeneca site in Macclesfield

(Reuters) - AstraZeneca Plc immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head and neck cancer, the London-listed drugmaker said on Friday.

The study, known as "EAGLE", did not improve overall survival compared with standard chemotherapy in patients with the hard-to-treat disease, the company said.

The results come after AstraZeneca warned last month that its immunotherapy treatment Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.

AstraZeneca has been seen as having a head start in the race for cancer treatments, and Imfinzi was aiming to be the new standard of care in treating early inoperable stage III lung cancer.

"While these results are disappointing, we remain committed to evaluating the potential of Imfinzi and other innovative medicines for patients with head and neck cancer," said Chief Medical Officer Sean Bohen.

The trial was conducted at 169 centres across 24 countries including the U.S., Europe, South America, Japan, Korea, Taiwan, Israel and Australia, AstraZeneca said.

(Reporting by Sangameswaran S and Noor Zainab Hussain in Bengaluru; Editing by Sai Sachin Ravikumar, Bernard Orr)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
05/22LONDON STOCK EXCHANGE : Brexit worries hit domestic stocks but sterling slide li..
RE
05/22ASTRAZENECA : Bob Harper and AstraZeneca Expand Survivors Have Heart Initiative ..
BU
05/20ASTRAZENECA : FASENRA® (benralizumab) reduces oral corticosteroid use and mainta..
BU
05/20ASTRAZENECA : New data show Symbicort reduces attacks in mild asthma when used a..
PU
05/16ASTRAZENECA : New data on Symbicort as a potential anti-inflammatory reliever in..
PU
05/16ASTRAZENECA : continues to redefine cancer treatment at the 2019 ASCO Annual Mee..
PU
05/10Exporters lead FTSE 100 lower after dollar dips on trade hopes
RE
05/10Forty Seven to Work With AstraZeneca's Acerta in Lymphoma Study
DJ
05/10AstraZeneca Safety Analyses for Roxadustat Show Top-Line Results
DJ
05/10ASTRAZENECA : Pooled analyses of the roxadustat global Phase III
AQ
More news
Financials ($)
Sales 2019 23 580 M
EBIT 2019 6 339 M
Net income 2019 3 075 M
Debt 2019 12 321 M
Yield 2019 3,67%
P/E ratio 2019 35,78
P/E ratio 2020 26,38
EV / Sales 2019 4,76x
EV / Sales 2020 4,33x
Capitalization 99 865 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 85,3 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA2.38%99 865
JOHNSON & JOHNSON7.52%368 416
PFIZER-3.80%233 461
ROCHE HOLDING LTD.9.84%228 186
NOVARTIS13.31%210 460
MERCK AND COMPANY5.98%208 495